IMMULITE 2000 AFP
Siemens Healthcare Diagnostics, Inc. · Decision date Jul 27, 2026
What did the FDA decide?
FDA records P010007/S026 as a supplement to PMA P010007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 27, 2026.
FDA approval order statement
Approval of the change to in-process manufacturing quality testing for the IMMULITE 2000 XPi analyzers and IMMULITE 2000 / IMMULITE 2000 XPi spare probe assemblies.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Jul 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010007/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- Decision code
- OK30
- Decision date
- Jul 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010007. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010007 · Original PMA
IMMULITE/IMMULITE 1000 AFP AND IMMULITE 2000/IMMULITE 2500 AFP
P010007/S024 · Related supplement
IMMULITE 2000 AFP
P010007/S025 · Related supplement
IMMULITE 2000 AFP
P010007/S026 received
Application receipt date recorded by FDA.
P010007/S026 · FDA decision
30-Day Notice
P010007/S027 · Related supplement
IMMULITE Systems AFP
P010007/S028 · Related supplement
IMMULITE Systems AFP
Timeline entries are records held by MedtechLedger for P010007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Siemens Healthcare Diagnostics, Inc. | PMA approval | Nov 9, 2001 | FDA | |
IMMULITE 2000 AFPP010007/S024 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 30, 2025 | FDA |
IMMULITE 2000 AFPP010007/S025 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
IMMULITE Systems AFPP010007/S027 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE Systems AFPP010007/S028 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LOK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | May 11, 2026 | FDA | |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S031 | ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
Access AFP (on DxI 9000 Analyzer)P980041/S051 | BECKMAN COULTER, INC. | PMA supplement | Nov 3, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 511 Benedict Ave., Tarrytown, NY, 10591
Sources and methodology
- Original FDA record: P010007/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





